We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GSK (GSK) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
GSK (GSK - Free Report) closed the most recent trading day at $41.79, moving -1.49% from the previous trading session. This change lagged the S&P 500's 0.72% loss on the day. Elsewhere, the Dow lost 1%, while the tech-heavy Nasdaq lost 0.95%.
Prior to today's trading, shares of the drug developer had lost 0.05% over the past month. This has lagged the Medical sector's loss of 0.03% and the S&P 500's gain of 2.16% in that time.
Market participants will be closely following the financial results of GSK in its upcoming release. The company plans to announce its earnings on May 1, 2024. The company is expected to report EPS of $0.95, up 5.56% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $8.99 billion, up 6.47% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $4.03 per share and revenue of $39.85 billion. These totals would mark changes of +4.4% and +5.56%, respectively, from last year.
Any recent changes to analyst estimates for GSK should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 0.51% fall in the Zacks Consensus EPS estimate. GSK currently has a Zacks Rank of #3 (Hold).
In terms of valuation, GSK is currently trading at a Forward P/E ratio of 10.53. This signifies a discount in comparison to the average Forward P/E of 23.46 for its industry.
It's also important to note that GSK currently trades at a PEG ratio of 1.94. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. GSK's industry had an average PEG ratio of 1.75 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 74, which puts it in the top 30% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GSK (GSK) Registers a Bigger Fall Than the Market: Important Facts to Note
GSK (GSK - Free Report) closed the most recent trading day at $41.79, moving -1.49% from the previous trading session. This change lagged the S&P 500's 0.72% loss on the day. Elsewhere, the Dow lost 1%, while the tech-heavy Nasdaq lost 0.95%.
Prior to today's trading, shares of the drug developer had lost 0.05% over the past month. This has lagged the Medical sector's loss of 0.03% and the S&P 500's gain of 2.16% in that time.
Market participants will be closely following the financial results of GSK in its upcoming release. The company plans to announce its earnings on May 1, 2024. The company is expected to report EPS of $0.95, up 5.56% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $8.99 billion, up 6.47% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $4.03 per share and revenue of $39.85 billion. These totals would mark changes of +4.4% and +5.56%, respectively, from last year.
Any recent changes to analyst estimates for GSK should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 0.51% fall in the Zacks Consensus EPS estimate. GSK currently has a Zacks Rank of #3 (Hold).
In terms of valuation, GSK is currently trading at a Forward P/E ratio of 10.53. This signifies a discount in comparison to the average Forward P/E of 23.46 for its industry.
It's also important to note that GSK currently trades at a PEG ratio of 1.94. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. GSK's industry had an average PEG ratio of 1.75 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 74, which puts it in the top 30% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.